WallStreetZenWallStreetZen

NASDAQ: ASLN
Aslan Pharmaceuticals Ltd Stock

$0.54+0.01 (+1.89%)
Updated Apr 11, 2024
ASLN Price
$0.54
Fair Value Price
$1.38
Market Cap
$9.29M
52 Week Low
$0.39
52 Week High
$4.69
P/E
-0.2x
P/B
-10.54x
P/S
0.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.00M
Earnings
-$44.22M
Gross Margin
100%
Operating Margin
-340.87%
Profit Margin
-376.6%
Debt to Equity
-51.62
Operating Cash Flow
-$43M
Beta
0.78
Next Earnings
Apr 26, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ASLN Overview

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ASLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ASLN ($0.54) is undervalued by 60.93% relative to our estimate of its Fair Value price of $1.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ASLN ($0.54) is significantly undervalued by 60.93% relative to our estimate of its Fair Value price of $1.38 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ASLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ASLN due diligence checks available for Premium users.

Be the first to know about important ASLN news, forecast changes, insider trades & much more!

ASLN News

Valuation

ASLN fair value

Fair Value of ASLN stock based on Discounted Cash Flow (DCF)
Price
$0.54
Fair Value
$1.38
Undervalued by
60.93%
ASLN ($0.54) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ASLN ($0.54) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ASLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ASLN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.2x
Industry
14.34x
Market
43.63x

ASLN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-10.54x
Industry
6.04x

ASLN's financial health

Profit margin

Revenue
$0.0
Net Income
-$13.5M
Profit Margin
0%
ASLN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$24.6M
Liabilities
$37.9M
Debt to equity
-2.85
ASLN's short-term assets ($44.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASLN's short-term assets ($44.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

ASLN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ASLN$9.29M+1.69%-0.20x-10.54x
CANF$9.30M-2.98%-0.76x1.49x
VIRI$9.24M+3.23%-1.71x2.43x
KZIA$9.49M-15.69%-0.98x2.74x
HEPA$9.67M-2.19%-0.18x0.60x

Aslan Pharmaceuticals Stock FAQ

What is Aslan Pharmaceuticals's quote symbol?

(NASDAQ: ASLN) Aslan Pharmaceuticals trades on the NASDAQ under the ticker symbol ASLN. Aslan Pharmaceuticals stock quotes can also be displayed as NASDAQ: ASLN.

If you're new to stock investing, here's how to buy Aslan Pharmaceuticals stock.

What is the 52 week high and low for Aslan Pharmaceuticals (NASDAQ: ASLN)?

(NASDAQ: ASLN) Aslan Pharmaceuticals's 52-week high was $4.69, and its 52-week low was $0.39. It is currently -88.49% from its 52-week high and 37.76% from its 52-week low.

How much is Aslan Pharmaceuticals stock worth today?

(NASDAQ: ASLN) Aslan Pharmaceuticals currently has 430,057,627 outstanding shares. With Aslan Pharmaceuticals stock trading at $0.54 per share, the total value of Aslan Pharmaceuticals stock (market capitalization) is $9.29M.

Aslan Pharmaceuticals stock was originally listed at a price of $28.05 in May 4, 2018. If you had invested in Aslan Pharmaceuticals stock at $28.05, your return over the last 5 years would have been -98.07%, for an annualized return of -54.62% (not including any dividends or dividend reinvestments).

How much is Aslan Pharmaceuticals's stock price per share?

(NASDAQ: ASLN) Aslan Pharmaceuticals stock price per share is $0.54 today (as of Apr 11, 2024).

What is Aslan Pharmaceuticals's Market Cap?

(NASDAQ: ASLN) Aslan Pharmaceuticals's market cap is $9.29M, as of Apr 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aslan Pharmaceuticals's market cap is calculated by multiplying ASLN's current stock price of $0.54 by ASLN's total outstanding shares of 430,057,627.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.